FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present in vivo data from its T-cell therapy platform at this year’s AACR Annual Meeting. These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024. Please find the link to the abstract here. Celularity i ...